Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study
• Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ruffatti, Amelia [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The use of serum marker CA-125 in patients operated because of endometriosis - Georgievska, J. ELSEVIER, 2019, the international journal for experimental and clinical reproductive immunobiology, Oxford |
|---|---|
| Übergeordnetes Werk: |
volume:115 ; year:2016 ; pages:14-19 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jri.2016.03.004 |
|---|
| Katalog-ID: |
ELV029510902 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029510902 | ||
| 003 | DE-627 | ||
| 005 | 20230623201514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jri.2016.03.004 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016004000003.pica |
| 035 | |a (DE-627)ELV029510902 | ||
| 035 | |a (ELSEVIER)S0165-0378(15)30042-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a 35.00 |2 bkl | ||
| 084 | |a 44.46 |2 bkl | ||
| 100 | 1 | |a Ruffatti, Amelia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study |
| 264 | 1 | |c 2016 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. | ||
| 650 | 7 | |a LMWH |2 Elsevier | |
| 650 | 7 | |a APS |2 Elsevier | |
| 650 | 7 | |a HELLP |2 Elsevier | |
| 650 | 7 | |a a-β2GPI |2 Elsevier | |
| 650 | 7 | |a LDA |2 Elsevier | |
| 650 | 7 | |a IVIG |2 Elsevier | |
| 650 | 7 | |a aCL |2 Elsevier | |
| 650 | 7 | |a aPL |2 Elsevier | |
| 650 | 7 | |a LAC |2 Elsevier | |
| 700 | 1 | |a Favaro, Maria |4 oth | |
| 700 | 1 | |a Hoxha, Ariela |4 oth | |
| 700 | 1 | |a Zambon, Alessandra |4 oth | |
| 700 | 1 | |a Marson, Piero |4 oth | |
| 700 | 1 | |a Del Ross, Teresa |4 oth | |
| 700 | 1 | |a Calligaro, Antonia |4 oth | |
| 700 | 1 | |a Tonello, Marta |4 oth | |
| 700 | 1 | |a Nardelli, Giovanni B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Oxford University Press |a Georgievska, J. ELSEVIER |t The use of serum marker CA-125 in patients operated because of endometriosis |d 2019 |d the international journal for experimental and clinical reproductive immunobiology |g Oxford |w (DE-627)ELV002243032 |
| 773 | 1 | 8 | |g volume:115 |g year:2016 |g pages:14-19 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jri.2016.03.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.00 |j Chemie: Allgemeines |q VZ |
| 936 | b | k | |a 44.46 |j Klinische Pathologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 115 |j 2016 |h 14-19 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a r ar |
|---|---|
| matchkey_str |
ruffattiameliafavaromariahoxhaarielazamb:2016----:peeiadnrvnuimngouissdndiinoovninlhrpttetihikrgatnihshlpdn |
| hierarchy_sort_str |
2016 |
| bklnumber |
35.00 44.46 |
| publishDate |
2016 |
| allfields |
10.1016/j.jri.2016.03.004 doi GBVA2016004000003.pica (DE-627)ELV029510902 (ELSEVIER)S0165-0378(15)30042-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl Ruffatti, Amelia verfasserin aut Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 2016 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Elsevier Favaro, Maria oth Hoxha, Ariela oth Zambon, Alessandra oth Marson, Piero oth Del Ross, Teresa oth Calligaro, Antonia oth Tonello, Marta oth Nardelli, Giovanni B. oth Enthalten in Oxford University Press Georgievska, J. ELSEVIER The use of serum marker CA-125 in patients operated because of endometriosis 2019 the international journal for experimental and clinical reproductive immunobiology Oxford (DE-627)ELV002243032 volume:115 year:2016 pages:14-19 extent:6 https://doi.org/10.1016/j.jri.2016.03.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ 44.46 Klinische Pathologie VZ AR 115 2016 14-19 6 045F 610 |
| spelling |
10.1016/j.jri.2016.03.004 doi GBVA2016004000003.pica (DE-627)ELV029510902 (ELSEVIER)S0165-0378(15)30042-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl Ruffatti, Amelia verfasserin aut Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 2016 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Elsevier Favaro, Maria oth Hoxha, Ariela oth Zambon, Alessandra oth Marson, Piero oth Del Ross, Teresa oth Calligaro, Antonia oth Tonello, Marta oth Nardelli, Giovanni B. oth Enthalten in Oxford University Press Georgievska, J. ELSEVIER The use of serum marker CA-125 in patients operated because of endometriosis 2019 the international journal for experimental and clinical reproductive immunobiology Oxford (DE-627)ELV002243032 volume:115 year:2016 pages:14-19 extent:6 https://doi.org/10.1016/j.jri.2016.03.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ 44.46 Klinische Pathologie VZ AR 115 2016 14-19 6 045F 610 |
| allfields_unstemmed |
10.1016/j.jri.2016.03.004 doi GBVA2016004000003.pica (DE-627)ELV029510902 (ELSEVIER)S0165-0378(15)30042-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl Ruffatti, Amelia verfasserin aut Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 2016 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Elsevier Favaro, Maria oth Hoxha, Ariela oth Zambon, Alessandra oth Marson, Piero oth Del Ross, Teresa oth Calligaro, Antonia oth Tonello, Marta oth Nardelli, Giovanni B. oth Enthalten in Oxford University Press Georgievska, J. ELSEVIER The use of serum marker CA-125 in patients operated because of endometriosis 2019 the international journal for experimental and clinical reproductive immunobiology Oxford (DE-627)ELV002243032 volume:115 year:2016 pages:14-19 extent:6 https://doi.org/10.1016/j.jri.2016.03.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ 44.46 Klinische Pathologie VZ AR 115 2016 14-19 6 045F 610 |
| allfieldsGer |
10.1016/j.jri.2016.03.004 doi GBVA2016004000003.pica (DE-627)ELV029510902 (ELSEVIER)S0165-0378(15)30042-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl Ruffatti, Amelia verfasserin aut Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 2016 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Elsevier Favaro, Maria oth Hoxha, Ariela oth Zambon, Alessandra oth Marson, Piero oth Del Ross, Teresa oth Calligaro, Antonia oth Tonello, Marta oth Nardelli, Giovanni B. oth Enthalten in Oxford University Press Georgievska, J. ELSEVIER The use of serum marker CA-125 in patients operated because of endometriosis 2019 the international journal for experimental and clinical reproductive immunobiology Oxford (DE-627)ELV002243032 volume:115 year:2016 pages:14-19 extent:6 https://doi.org/10.1016/j.jri.2016.03.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ 44.46 Klinische Pathologie VZ AR 115 2016 14-19 6 045F 610 |
| allfieldsSound |
10.1016/j.jri.2016.03.004 doi GBVA2016004000003.pica (DE-627)ELV029510902 (ELSEVIER)S0165-0378(15)30042-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl Ruffatti, Amelia verfasserin aut Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 2016 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Elsevier Favaro, Maria oth Hoxha, Ariela oth Zambon, Alessandra oth Marson, Piero oth Del Ross, Teresa oth Calligaro, Antonia oth Tonello, Marta oth Nardelli, Giovanni B. oth Enthalten in Oxford University Press Georgievska, J. ELSEVIER The use of serum marker CA-125 in patients operated because of endometriosis 2019 the international journal for experimental and clinical reproductive immunobiology Oxford (DE-627)ELV002243032 volume:115 year:2016 pages:14-19 extent:6 https://doi.org/10.1016/j.jri.2016.03.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ 44.46 Klinische Pathologie VZ AR 115 2016 14-19 6 045F 610 |
| language |
English |
| source |
Enthalten in The use of serum marker CA-125 in patients operated because of endometriosis Oxford volume:115 year:2016 pages:14-19 extent:6 |
| sourceStr |
Enthalten in The use of serum marker CA-125 in patients operated because of endometriosis Oxford volume:115 year:2016 pages:14-19 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Chemie: Allgemeines Klinische Pathologie |
| institution |
findex.gbv.de |
| topic_facet |
LMWH APS HELLP a-β2GPI LDA IVIG aCL aPL LAC |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The use of serum marker CA-125 in patients operated because of endometriosis |
| authorswithroles_txt_mv |
Ruffatti, Amelia @@aut@@ Favaro, Maria @@oth@@ Hoxha, Ariela @@oth@@ Zambon, Alessandra @@oth@@ Marson, Piero @@oth@@ Del Ross, Teresa @@oth@@ Calligaro, Antonia @@oth@@ Tonello, Marta @@oth@@ Nardelli, Giovanni B. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002243032 |
| dewey-sort |
3610 |
| id |
ELV029510902 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029510902</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201514.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jri.2016.03.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016004000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029510902</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0165-0378(15)30042-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.46</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruffatti, Amelia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LMWH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">APS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HELLP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">a-β2GPI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IVIG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aCL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aPL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LAC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Favaro, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoxha, Ariela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zambon, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marson, Piero</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Del Ross, Teresa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calligaro, Antonia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tonello, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nardelli, Giovanni B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Oxford University Press</subfield><subfield code="a">Georgievska, J. ELSEVIER</subfield><subfield code="t">The use of serum marker CA-125 in patients operated because of endometriosis</subfield><subfield code="d">2019</subfield><subfield code="d">the international journal for experimental and clinical reproductive immunobiology</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV002243032</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:115</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:14-19</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jri.2016.03.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.46</subfield><subfield code="j">Klinische Pathologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">115</subfield><subfield code="j">2016</subfield><subfield code="h">14-19</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ruffatti, Amelia |
| spellingShingle |
Ruffatti, Amelia ddc 610 ddc 540 bkl 35.00 bkl 44.46 Elsevier LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study |
| authorStr |
Ruffatti, Amelia |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002243032 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC Elsevier |
| topic |
ddc 610 ddc 540 bkl 35.00 bkl 44.46 Elsevier LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC |
| topic_unstemmed |
ddc 610 ddc 540 bkl 35.00 bkl 44.46 Elsevier LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC |
| topic_browse |
ddc 610 ddc 540 bkl 35.00 bkl 44.46 Elsevier LMWH Elsevier APS Elsevier HELLP Elsevier a-β2GPI Elsevier LDA Elsevier IVIG Elsevier aCL Elsevier aPL Elsevier LAC |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m f mf a h ah a z az p m pm r t d rt rtd a c ac m t mt g b n gb gbn |
| hierarchy_parent_title |
The use of serum marker CA-125 in patients operated because of endometriosis |
| hierarchy_parent_id |
ELV002243032 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
The use of serum marker CA-125 in patients operated because of endometriosis |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002243032 |
| title |
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study |
| ctrlnum |
(DE-627)ELV029510902 (ELSEVIER)S0165-0378(15)30042-5 |
| title_full |
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study |
| author_sort |
Ruffatti, Amelia |
| journal |
The use of serum marker CA-125 in patients operated because of endometriosis |
| journalStr |
The use of serum marker CA-125 in patients operated because of endometriosis |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
14 |
| author_browse |
Ruffatti, Amelia |
| container_volume |
115 |
| physical |
6 |
| class |
610 610 DE-600 540 610 VZ 35.00 bkl 44.46 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ruffatti, Amelia |
| doi_str_mv |
10.1016/j.jri.2016.03.004 |
| dewey-full |
610 540 |
| title_sort |
apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. a prospective study |
| title_auth |
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study |
| abstract |
• Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. |
| abstractGer |
• Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. |
| abstract_unstemmed |
• Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study |
| url |
https://doi.org/10.1016/j.jri.2016.03.004 |
| remote_bool |
true |
| author2 |
Favaro, Maria Hoxha, Ariela Zambon, Alessandra Marson, Piero Del Ross, Teresa Calligaro, Antonia Tonello, Marta Nardelli, Giovanni B. |
| author2Str |
Favaro, Maria Hoxha, Ariela Zambon, Alessandra Marson, Piero Del Ross, Teresa Calligaro, Antonia Tonello, Marta Nardelli, Giovanni B. |
| ppnlink |
ELV002243032 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jri.2016.03.004 |
| up_date |
2024-07-06T21:39:16.083Z |
| _version_ |
1803867343903784960 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029510902</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201514.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jri.2016.03.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016004000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029510902</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0165-0378(15)30042-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.46</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruffatti, Amelia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies. • Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established. • Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy. • The combined therapy outlined here led to a high birth rate and no side-effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LMWH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">APS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HELLP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">a-β2GPI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IVIG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aCL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aPL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LAC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Favaro, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoxha, Ariela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zambon, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marson, Piero</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Del Ross, Teresa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calligaro, Antonia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tonello, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nardelli, Giovanni B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Oxford University Press</subfield><subfield code="a">Georgievska, J. ELSEVIER</subfield><subfield code="t">The use of serum marker CA-125 in patients operated because of endometriosis</subfield><subfield code="d">2019</subfield><subfield code="d">the international journal for experimental and clinical reproductive immunobiology</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV002243032</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:115</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:14-19</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jri.2016.03.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.46</subfield><subfield code="j">Klinische Pathologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">115</subfield><subfield code="j">2016</subfield><subfield code="h">14-19</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4028835 |